July 2021 EGRP Cancer Epidemiology News

EGRP Cancer Epidemiology News


Opportunities in Obesity and Cancer Research

Obesity is a major contributor to serious health conditions, including many forms of cancer. As rates of obesity have soared in the United States, increasing the number of people who achieve and maintain a healthy weight is a critical public health goal. Likewise, research focusing on understanding the etiology of obesity-associated cancers is an important component of a larger transdisciplinary effort for cancer control and prevention.

The National Institutes of Health (NIH), including the National Cancer Institute (NCI), funds a broad spectrum of research on obesity. Some of the important obesity research supported by NCI is described in NCI’s Annual Plan for Fiscal Year 2022. Additionally, program staff across multiple NCI divisions formed the Trans-NCI Obesity and Cancer Working Group in 2019 to identify and promote new opportunities in obesity and cancer research.

New Obesity-Focused Funding Opportunities

Two recently published funding opportunity announcements (FOAs) that staff in NCI’s Epidemiology and Genomics Research Program (EGRP) in DCCPS, along with staff in the Division of Cancer Biology and Division of Cancer Prevention, developed include RFA-CA-21-021 and RFA-CA-21-022.

Through these FOAs, NCI invites applications for transdisciplinary studies that will enhance knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and increased cancer risk as part of the Metabolic Dysregulation and Cancer Risk Program. Metabolic dysregulation, in the context of these FOAs, is defined as alterations in glucose utilization and storage, insulin sensitivity, and/or lipid metabolism. Applications should specifically seek to advance the understanding of how metabolic dysregulation in individuals affects cancer risk and identify mechanisms that will enhance cancer risk prediction, screening for high-risk individuals in clinical settings, and identify potential targets for preventative and therapeutic interventions.

NCI will hold a pre-application webinar on August 11, 2021. The event will be recorded for those who are not able to participate in the live event.

Related Resources

The Trans-NCI Working Group’s website includes information about additional funding opportunity announcements that NCI participates in related to obesity research. Additionally, this site includes information about upcoming webinars, such as the September 9, 2021 presentation discussing mechanistic considerations for obesity, the microbiome, and cancer; and other NCI- and NIH-related obesity research resources.

Funding Opportunities & Notices of Special Interest (NOSI)

  • Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01, Basic Experimental Studies with Humans; R01, Clinical Trials Not Allowed)
  • HIV-Associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21, Clinical Trial Optional)
  • Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01, Clinical Trial Not Allowed)
  • Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-Associated Research
    • Research Grants (U01, Clinical Trial Optional)
    • Coordinating Center (U24, Clinical Trial Not Allowed)
    • Note: A pre-application webinar will be held on August 11, 2021 (NOT-CA-21-094).
  • NCI Research Specialist Award
    • Laboratory-based Scientist (R50, Clinical Trial Not Allowed)
    • Core-based Scientist (R50, Clinical Trial Not Allowed)
  • NOSI: Integration of Individual Residential Histories in Cancer Research (NOT-CA-21-092)
  • NOSI: NCI SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (NOT-CA-21-062)
  • NOSI: Alzheimer's-Focused Administrative Supplements for NIH Grants that are Not Focused on Alzheimer's Disease (NOT-AG-21-018)
  • Small Business Innovation Research
    • Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44], Clinical Trial Not Allowed)
    • PHS 2021-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44], Clinical Trial Required)
  • Small Business Technology Transfer
    • PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42], Clinical Trial Required)
    • PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42], Clinical Trial Not Allowed)
  • Notice of Intent to Publish a Research Opportunity Announcement for AIM-AHEAD: Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity (NOT-OD-21-156)

Requests for Information

  • Developing Consent Language for Future Use of Data and Biospecimens (NOT-OD-21-131, responses due by September 29, 2021)
  • NIH Programs to Increase Cloud Computing to Diverse Biomedical Research Institutions (NOT-OD-21-158, responses due by September 30, 2021)
  • Climate Change and Health (NOT-ES-21-009)
  • Streamlining Access to Controlled Data from NIH Data Repositories (NOT-OD-21-157, responses due by August 9, 2021)

Grants Policy Notices and Grant-Writing Resources

Research Resources

Training Opportunities

NCI & NIH News

Stay Connected

Subscribe for Updates

Subscribe
You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.

Subscribe to the E-Newsletter

Need Help?

EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.

Email Us
(240) 276-6730